2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139866
    SARS-CoV-2-IN-9
    		Inhibitor
    SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease.
    SARS-CoV-2-IN-9
  • HY-17430S1
    Amprenavir-d4-1
    		Inhibitor
    Amprenavir-d4-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir-d<sub>4</sub>-1
  • HY-145276
    SARS-CoV-2-IN-10
    		Inhibitor
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
    SARS-CoV-2-IN-10
  • HY-B0260S2
    Methylprednisolone-d4
    		Inhibitor
    Methylprednisolone-d4 is deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
    Methylprednisolone-d<sub>4</sub>
  • HY-P11464
    SARS-CoV-2 Spike receptor binding domain, RBD (371-394)
    SARS-CoV-2 Spike receptor binding domain, RBD (371-394) is a peptide from SARS-CoV-2 spike receptor-binding domain. SARS-CoV-2 spike protein receptor-binding domain binds to ACE2. SARS-CoV-2 Spike receptor binding domain, RBD (371-394) can be used in the research of SARS-CoV-2 infection.
    SARS-CoV-2 Spike receptor binding domain, RBD (371-394)
  • HY-156979
    RBT-9
    		Inhibitor
    RBT-9 prevents progression to severe COVID-19 and organ failure. RBT-9 also has antiviral effects, as demonstrated in several enveloped viruses, including influenza, HCV, dengue, and yellow fever.
    RBT-9
  • HY-174233
    PROTAC SARS-CoV-2 Mpro degrader-4
    		Degrader
    PROTAC SARS-CoV-2 Mpro degrader-4 (Compound LLP019) is a SARS-CoV-2 MPro PROTAC degrader with a DC50 value of 4.7 μM. PROTAC SARS-CoV-2 Mpro degrader-4 induces MPro ubiquitination and proteasomal degradation to inhibit SARS-CoV-2 replication. PROTAC SARS-CoV-2 Mpro degrader-4 is promising for research of COVID-19 and related coronavirus infections. (Pink: DH03 (HY-32717); Black: linker (HY-42149); Blue: Thalidomide-4-O-CH2-COO(t-Bu) (HY-42771).
    PROTAC SARS-CoV-2 Mpro degrader-4
  • HY-152224
    SPR41
    		Inhibitor
    SPR41 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.184, 0.252, 14.4 µM for SARS-CoV-2 Mpro, hCatL, hCatB, respectively. SPR41 shows antiviral and cytotoxicity.
    SPR41
  • HY-105721
    Aranotin
    		Inhibitor
    Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising SARS-CoV-2 replication strong inhibitor. Aranotin has the potential for COVID-19 research.
    Aranotin
  • HY-154990
    RdRP-IN-7
    		Inhibitor
    RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC50 of 8.2 μM, an IC90 of 14.1 μM and an CC90 of 79.1 μM. RdRP-IN-7 can be used for antiviral research.
    RdRP-IN-7
  • HY-19088
    Oberadilol
    		Ligand
    Oberadilol (CID-3047798) is an ACE2 receptor binding agent. Oberadilol binds to the human ACE2 receptor and SARS-CoV proteins (Spike S glycoprotein, protease) with a Kd of 23.18 mM for the SARS-CoV-2 main protease.
    Oberadilol
  • HY-155734
    SARS-CoV-2-IN-55
    SARS-CoV-2-IN-55(compound 65) is a low cytotoxicity inhibtor of SARS-CoV-2 with an IC50 value of 0.3 μM, by the direct interaction with VSV-S pseudoparticles.
    SARS-CoV-2-IN-55
  • HY-155015
    SARS-CoV-2-IN-45
    		Inhibitor
    SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC50 of 0.5 μM, and has no evident cytotoxic effect.
    SARS-CoV-2-IN-45
  • HY-146987
    FWM-3
    		Inhibitor
    FWM-3 is a potent SARS-CoV-2 NSP13 helicase inhibitor.
    FWM-3
  • HY-124439
    Setomimycin
    		Inhibitor
    Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC50 value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity.
    Setomimycin
  • HY-163706
    SARS-CoV-2-IN-88
    		Inhibitor
    SARS-CoV-2-IN-88 (compound 3a) is a potent SARS-CoV-2 inhibitor with inhibitory value of 96.00%.
    SARS-CoV-2-IN-88
  • HY-N10604
    Dihydromaniwamycin E
    		Inhibitor
    Dihydromaniwamycin E is a heat-shock metabolite with antiviral activity against influenza and SARS-CoV-2 viruses.
    Dihydromaniwamycin E
  • HY-168152
    SARS-CoV-2 3CLpro-IN-26
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells.
    SARS-CoV-2 3CLpro-IN-26
  • HY-147804
    SARS-CoV-2 3CLpro-IN-3
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities.
    SARS-CoV-2 3CLpro-IN-3
  • HY-181661
    YL1004
    		Inhibitor
    YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PLpro). YL1004 shows an IC50 of 17.5 nM and a Ki of 2.3 nM against PLpro, with an in vitro anti-SARS-CoV-2 EC50 of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PLpro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection).
    YL1004
Cat. No. Product Name / Synonyms Species Source